Table 4.
24 Week change of neuropsychological tests, NPZ-8, and GDS by treatment, As Treated (N=22)
| No Paroxetine arms mean (SD) | Paroxetine arms mean (SD) | p value | No Fluconazole arms mean (SD) | Fluconazole arms mean (SD) | p value | |
|---|---|---|---|---|---|---|
| N=8 | N=13 | N=12 | N=9 | |||
| CalCAP Choice Reaction time change * | −0.66 (1.59) | 0.85 (2.45) | 0.978 | 0.91 (2.68) | −0.54 (0.96) | 0.115 |
| CalCAP Sequential Reaction time change * | −0.35 (0.40) | 0.59 (1.23) | 0.039 | 0.30 (1.29) | 0.29 (0.83) | 0.782 |
| Symbol Digit change | −0.18 (0.87) | 0.31 (0.81) | 0.143 | 0.09 (0.93) | 0.18 (0.77) | 0.578 |
| Trail Making Part A change | 0.39 (0.94) | 0.00 (0.79) | 0.520 | 0.36 (0.76) | −0.13 (0.93) | 0.374 |
| Trail Making Part B change | −0.21 (1.02) | 0.55 (0.88) | 0.619 | 0.35 (0.74) | 0.14 (1.28) | 0.237 |
| Timed Gait change ** | −0.43 (1.20) | −0.09 (1.15) | 0.958 | −0.01 (1.13) | −0.48 (1.19) | 0.906 |
| Grooved Pegboard Dominant change | −0.34 (0.91) | 0.38 (1.15) | 0.128 | 0.28 (1.18) | −0.12 (1.01) | 0.466 |
| Grooved Pegboard non-dominant change | −0.21 (0.77) | 0.15 (1.16) | 0.484 | 0.07 (0.96) | −0.07 (1.15) | 0.847 |
| Hopkins Auditory Verbal Learning test Total change | 0.42 (0.92) | 0.18 (0.95) | 0.086 | 0.04 (0.83) | 0.57 (1.01) | 0.224 |
| Hopkins Auditory Verbal Learning test Delayed change | 0.45 (0.92) | 0.30 (0.98) | 0.833 | 0.41 (0.79) | 0.28 (1.16) | 0.378 |
| Rey Complex Figure Copy Change | 0.12 (1.11) | 0.02 (0.94) | 0.715 | 0.22 (1.00) | −0.16 (0.98) | 0.464 |
| Rey Complex Figure Delayed change | 0.17 (0.51) | 0.28 (0.41) | 0.813 | 0.27 (0.55) | 0.19 (0.26) | 0.560 |
| Stroop Color Interference change *** | 0.39 (0.71) | −0.27 (1.45) | 0.173 | −0.04 (1.59) | 0.04 (0.37) | 0.766 |
| Letter number sequencing change | 0.24 (0.83) | −0.47 (0.82) | 0.011 | −0.23 (0.93) | −0.16 (0.85) | 0.675 |
| FAS verbal fluency change | 0.16 (0.53) | 0.08 (0.33) | 0.620 | 0.23 (0.42) | −0.04 (0.33) | 0.032 |
| CES-D | −7.75 (10.28) | −0.36 (3.18) | 0.145 | −3.00 (6.70) | −3.11 (8.74) | 0.256 |
| NPZ-8 | −0.23 (0.16) | 0.35 (0.62) | 0.351 | 0.30 (0.61) | −0.10 (0.44) | 0.145 |
| GDS**** | 0.02 (0.17) | −0.12 (0.28) | 0.954 | −0.12 (0.27) | −0.01 (0.21) | 0.244 |
Models adjusted for baseline value, treatment effect on CES-D depression (with the exception of the model for changes in CES-D), hepatitis C serostatus, and plasma HIV RNA undetectable
Sample size (n) for this test: no paroxetine n=6, paroxetine n=13, no fluconazole n=12, fluconazole n=7
Sample size (n) for this test: no paroxetine n=8, paroxetine n=11, no fluconazole n=10, fluconazole n=9
Sample size (n) for this test: no paroxetine n=8, paroxetine n=12, no fluconazole n=12, fluconazole n=8
Higher numbers indicate worsening performance only for the GDS
CalCAP-California Computerized Reaction Time test
CES-D Center for Epidemiological Studies-Depression scale
GDS-Global deficit score
SD, standard deviation